102568Development of an Industrial Manufacturing Platform for Adeno-Associated Virus (AAV) production to support Regenerative Gene Therapy productsClosedCollaborative R&DInnovate UKGene therapy is becoming an increasingly important method of treatment for a variety of major unmet medical needs especially in the areas of inherited and rare diseases and diseases of the eye, conditions which are life threatening or significantly diminish quality of life. Adeno-associated virus (AAV) vectors are currently the delivery vehicle of choice for gene therapy treatments but the advancement of these treatments into clinical trials is currently hampered by the lack of scalabilty needed to manufacture these vectors. The proposed collaboration between Cobra and CPI will develop the scientific understanding to allow scalable flexibile process to be developed to manufacture AAV vectors. This will enable the acceleration of more potential products into clinical testing and ultimately new medicinces. This in turn will increase the chances of treatment being developed for a whole range of these currently intractable diseases.